Zhengye Biotechnology Holding Limited (Class A) (ZYBT) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Zhengye Biotechnology Holding Limited (Class A) (NASDAQ: ZYBT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $1.34 (+0.75% 1D, market cap $63.0M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, ZYBT ranks #445 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ZYBT carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of 20.5%, and ROIC of -22.3%. By comparison, CPIX (Cumberland Pharmaceuticals Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -16.4%, cap $63.2M) and FBIO (Fortress Biotech Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $64.4M). Among the 5-stock peer group, SPRO leads on earnings multiple (7.5x) while SPRO leads on capital efficiency (26.6% ROIC).
Per ZYBT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001975641), Zhengye Biotechnology Holding Limited (Class A) generated $16.6M in revenue (-34.8% YoY), -$10.0M in net income, and $1.8M in free cash flow against $62.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 10% of 52W Range • RSI-14 at 45.1 (NEUTRAL RANGE)
SEC XBRL FY 2025 (10-K): 10.6% FCF Margin ($1.8M FCF) & 20.5% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)
While ZYBT currently carries a cautious 41/100 (D-) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.45) and Max Pain ($1.41) forces dealer call-delta covering toward $8.41.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Zhengye Biotechnology Holding Limited (Class A) (ZYBT) advanced +0.75% to $1.34, trading at 10% of its 52-week range ($0.62 – $8.01). Stretched risk/reward at current multiples (-22% return on capital) under elevated 10-year interest-rate pressure.
The company issued a statement after a sharp increase in trading volume, saying it is unaware of any undisclosed developments that would explain the recent market activity. Key Investor TakeawaysZhengye Biotechnology (NA
Jilin, China, June 04, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing,
Jilin, China, April 06, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing,
Jilin, China, July 21, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing,
Jilin, China, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing,
Yahoo Finance coverage on ZYBT stock catalysts, institutional flow, and earnings outlook.
Jilin, China, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing,
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE5QWEdnZ3VYSGZNRUVROVI2OVVSbVJVVXJjU25sa0toM3FTU0xSQUtSelE4bkkxdHh3UlRfVVhpbldoT1AwRzFPRndhbVFWa3hBUnZGX3FaY3F0dFZfeHpvNW9adXJGSGM3NE9veDNfelktSmZGRGZaTw?oc=5
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNb0k3Q0xPNnV2TVVOd3dfY1NzVEVtRVU3LXVtT3ByNDN6a0xTSms2MDVEWS1XdDg2SFItZFFTaEVzVkdkMWpWRi0xS0ZJQWlDdVhPaGlYZ2prTTBVSGhzcElWU25reGJ0YW43WVNxTWN1cEhwLXhmajMyN2J
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxQNHZ5bEYxRy12QVRQN1JUYnYtVGxuVWVmdGFBUTNLVTJYMFZMaDMzM0Vla2dNamZzaUk4dGhHVVFEbTFtRWpRVnJsYWFrT1dvYUNPSEpPUEc5VVRlOTJmaU5KdC1BYUhmbEVKNzY5enJRbVM0VmV6eU51ZDN
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -34.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ZYBT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ZYBT. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Zhengye Biotechnology Holding Limited (Class A) (ZYBT) ranks #445 by composite RQD confidence (41/100, grade D-) and #710 by equity capitalization ($63.0M). Within this direct 5-issuer industry benchmark cohort, SPRO leads on earnings valuation at 7.5x trailing P/E, while SPRO leads on capital efficiency and profitability with 26.6% ROIC and — gross margin. INCR currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with ZYBT at 41/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ZYBT
ACTIVE
Zhengye Biotechnology Holding Limited (Class A) | D- | 41/100 | — | 20.5% | -22.3% | +0.75% | $63.0M | Benchmark Subject |
| CPIX Cumberland Pharmaceuticals Inc. | D- | 37/100 | — | 85.0% | -16.4% | +2.13% | $63.2M | /cpix-vs-zybt → |
| FBIO Fortress Biotech Inc. | E | 30/100 | — | 66.9% | -35.0% | +0.52% | $64.4M | /fbio-vs-zybt → |
| INCR Intercure Ltd. | D | 46/100 | — | — | — | -0.74% | $60.8M | /incr-vs-zybt → |
| SPRO Spero Therapeutics Inc. | D- | 40/100 | 7.5x | — | 26.6% | 0.00% | $60.6M | /spro-vs-zybt → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Zhengye Biotechnology Holding Limited (Class A) (ZYBT) reported GAAP revenue of $16.6M (-34.8% vs. FY2024 revenue of $25.5M ) , GAAP net income of -$10.0M, operating cash flow of $1.9M, and free cash flow of $1.8M (-53.0% YoY). On the balance sheet, ZYBT closed FY2025 with $62.4M in total assets against $0 in total debt (Altman Z-Score: 1.90, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $16.6M | -$10.0M | $1.9M | $1.8M | $62.4M | — |
| FY2024 (FY) | 2024-12-31 | $25.5M | $1.6M | $5.6M | $3.8M | $67.6M | $658.0K |
As of 2026-11-03, Zhengye Biotechnology Holding Limited (Class A) (NASDAQ: ZYBT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $1.34 (+0.75% 1D, market cap $63.0M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, ZYBT ranks #445 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ZYBT carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of 20.5%, and ROIC of -22.3%. By comparison, CPIX (Cumberland Pharmaceuticals Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -16.4%, cap $63.2M) and FBIO (Fortress Biotech Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $64.4M). Among the 5-stock peer group, SPRO leads on earnings multiple (7.5x) while SPRO leads on capital efficiency (26.6% ROIC).
Per ZYBT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001975641), Zhengye Biotechnology Holding Limited (Class A) generated $16.6M in revenue (-34.8% YoY), -$10.0M in net income, and $1.8M in free cash flow against $62.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
ZYBT last traded at $1.34 (+0.75% on volume of 4,776 shares), positioning the stock -7.59% below its 50-day simple moving average ($1.45) and +15.52% above its 200-day simple moving average ($1.16). Across its 52-week range of $0.62 to $8.01, ZYBT sits at the 9.7% percentile with a 14-day RSI of 45.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.17 to $1.51).
Zhengye Biotechnology Holding Limited (Class A) (ZYBT) earns a live Roarable RQD composite score of 41/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $1.34 (+0.75% 1D, market capitalization $63.0M).
Zhengye Biotechnology Holding Limited (Class A) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The company reported revenue of $16.6M for FY 2025 and $25.5M for FY 2024.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Zhengye Biotechnology Holding Limited (Class A) (ZYBT) reported $16.6M in annual revenue (up from $25.5M in FY2024, -34.8% YoY) and -$10.0M in GAAP net income. Over the multi-year SEC filing window from FY2024 ($25.5M revenue, $1.6M net income) through FY2025, ZYBT scaled operating cash flow to $1.9M and free cash flow to $1.8M, backed by $62.4M in total assets against $0 in total debt.
Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be identified from the source data.
Real-time company headlines, analyst actions, and sector developments for Zhengye Biotechnology Holding Limited (Class A) (ZYBT) • Click "Debate This Headline" to argue it in the Roar Pit below
The company issued a statement after a sharp increase in trading volume, saying it is unaware of any undisclosed developments that would explain the recent market activity. Key Investor TakeawaysZhengye Biotechnology (NA
Jilin, China, June 04, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing,
Jilin, China, April 06, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing,
Jilin, China, July 21, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing,
Jilin, China, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing,
Yahoo Finance coverage on ZYBT stock catalysts, institutional flow, and earnings outlook.
Jilin, China, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing,
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE5QWEdnZ3VYSGZNRUVROVI2OVVSbVJVVXJjU25sa0toM3FTU0xSQUtSelE4bkkxdHh3UlRfVVhpbldoT1AwRzFPRndhbVFWa3hBUnZGX3FaY3F0dFZfeHpvNW9adXJGSGM3NE9veDNfelktSmZGRGZaTw?oc=5
The stock trades at $1.3 with a positive 2.61% FCF yield despite the negative earnings profile.. When you look under the hood at ZYBT, Fundamental Cash Engine is 10/20 with 20.5% gross margins and -22.3% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (5/20) has been quietly accumulating below $8.01. My 12M target is $1.49.
@DeepValue_CFA Agree on the RQD 41/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.30 and keeping dry powder in case we test $1.21.
Fading this rally in ZYBT at $1.30. Operating income swung from $2.3M in FY 2024 to -$10.1M in FY 2025 with ROIC at -22.3%, and the RQD rating is a Roarable Sell.. With a beta of 1.0 and the stock sitting at $1.30 (52-wk range $0.62–$8.01), the easy multiple expansion is already priced in.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: